Battaglia L.,Fondazione Istituto Nazionale Dei Tumori |
Vannelli A.,Fondazione Istituto Nazionale Dei Tumori |
Belli F.,Fondazione Istituto Nazionale Dei Tumori |
Rampa M.,Fondazione Istituto Nazionale Dei Tumori |
And 3 more authors.
Tumori | Year: 2011
Buschke-Löwenstein tumor, or giant condyloma acuminatum, is a relatively uncommon lesion of the anus with aggressive local invasive behavior which may present as a large warty tumor of the genital region with expansive and destructive growth. Many sporadic reports have been published suggesting various therapeutic strategies. We report a case of Buschke-Löwenstein tumor treated with conservative surgery followed by reconstructive procedures without a loop colostomy. Source
Gasparini P.,Unit of Molecular Cytogenetics |
Facchinetti F.,Unit of Molecular Cytogenetics |
Boeri M.,Unit of Molecular Cytogenetics |
Lorenzetto E.,Centro Of Riferimento Oncologico |
And 13 more authors.
European Journal of Cancer | Year: 2011
Background: Epithelioid sarcoma (ES) is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults, presents a high rate of recurrences and metastases and frequently poses diagnostic dilemmas. In order to identify markers useful for patient stratification purposes, we investigated the prognostic impact of clinical and molecular patient characteristics, including the status of SMARCB1 tumour suppressor gene, in a consecutive series of ES cases. Methods: Kaplan-Meier survival curves were compared by the log-rank test. Immunophenotyping and SMARCB1 protein expression were analysed by immunohistochemistry or western blotting in 40 ES patients for which tumour material was available. Cases lacking SMARCB1 protein expression were investigated for the presence of gene mutations and gene deletions by exon sequencing, fluorescent in situ hybridization and quantitative PCR. Results: FNCLCC tumour grade 3 and proximal-type histology significantly correlated with shorter overall survival (log-rank p = 0.0046 and p = 0.0001, respectively). We identified loss of SMARCB1 protein expression in the majority of ES cases (25/40, 62.5%), including 24/34 (71%) adult cases but only 1/6 (17%) paediatric/adolescent cases (p = 0.02, two-tailed Fisher's exact test). The absence of protein is strongly correlated with SMARCB1 gene deletion (p = 0.003, two-tailed Fisher's exact test). We observed a trend towards the correlation between SMARCB1 inactivation and both higher tumour grading and a clinical course of the disease characterised by the occurrence of multiple relapses/metastasis. Conclusion: These data show that both tumour grading and subtype are prognostic factors in ES. Loss of SMARCB1 protein expression in ES is a frequent occurrence mediated by gene deletion events, thus pointing to a crucial role of SMARCB1 in ES genesis. Analysis of SMARCB1 status in ES warrants prospective investigation as a prognostic marker and therapeutic target. © 2010 Elsevier Ltd. All rights reserved. Source